1-Hydroxy-2(1H)-pyridinone-Based Chelators with Potential Catechol O-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease

Joseph C J Bergin (1) , Kean Kan Tan (1) , Anya K Nelson (1) , Cristina-Andreea Amarandei (2) , Véronique Hubscher-Bruder (2) , Jérémy Brandel (2) , Varvara Voinarovska (3) , Annick Dejaegere (3) , Roland H Stote (3) , David Tétard (1)

1 University of Northumbria at Newcastle [United Kingdom]
2 DSA-IPHC - Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires
3 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire

Two analogues of tolcapone where the nitrocatechol group has been replaced by a 1-hydroxy-2(1H)-pyridinone have been designed and synthesised. These compounds are expected to have a dual mode of action both beneficial against Parkinson’s disease: they are designed to be inhibitors of catechol O-methyl transferase, which contribute to the reduction of dopamine in the brain, and to protect neurons against oxidative damage. To assess whether these compounds are worthy of biological assessment to demonstrate these effects, measurement of their pKa and stability constants for Fe(III), in silico modelling of their potential to inhibit COMT and blood–brain barrier scoring were performed. These results demonstrate that the compounds may indeed have the desired properties, indicating they are indeed promising candidates for further evaluation.

Mots clés: 1-hydroxy-2(1H)-pyridinone; catechol O-methyl transferase; Parkinson’s disease; 1-hydroxy-2(1H)-pyridinone

Domaines: Chimie

Joseph C J Bergin, Kean Kan Tan, Anya K Nelson, Cristina-Andreea Amarandei, Véronique Hubscher-Bruder, et al.. 1-Hydroxy-2(1H)-pyridinone-Based Chelators with Potential Catechol O-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease. Molecules, 2022, 27 (9), pp.2816. ⟨10.3390/molecules27092816⟩. ⟨hal-03853711⟩